Skip to content
V1613-19 ·27 June 2019 ·consulta-vinculante Medium impact
Tax

Medicines derived from blood through pharmaceutical chemical processes are subject to 4% VAT

A company sought clarification on whether its new gene therapy product, manufactured from blood via genetic modification, was VAT exempt. The DGT ruled that the exemption for human body parts does not apply and that the reduced rate of 4% must be applied as it is a medicinal product for human use.

In 6 key points

How it affects those involved

This ruling clarifies the VAT treatment for advanced therapies derived from biological materials, confirming that they qualify for the reduced rate rather than being exempt.

Lifecycle

2019-06-27PublishedPublished in the BOE
Official text Based on BOE data (boe.es). Information, not advice.

Does this provision affect you?

The tax team reviews your specific situation.

Talk to the tax team
This analysis is informational only and does not constitute legal advice or create a client-adviser relationship. BM Consulting.
Email
Contact